30th Hong Kong Medical Forum (HKMF) 2026

Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), produces a sustained gastric acid suppression effect that is both more profound and more rapid than that of proton pump inhibitors (PPIs), making it an essential component of first-line (1L) and second-line (2L) therapy for Helicobacter pylori eradication, according to Professor Takashi Kawai of Tokyo Medical University Hospital, Tokyo, Japan.

Mainland China’s growing investment in medicine and biopharma is reshaping its research and healthcare landscape while creating new opportunities for Hong Kong – to contribute to, and benefit from – the next phase of development, noted Professor Chak-Sing Lau, Dean of Medicine, University of Hong Kong (HKU), at the 30^th Hong Kong Medical Forum